Market News Comments

Pfizer (PFE)

Pfizer Inc. announced that the Food and Drug Administration (FDA) issued a Complete Response letter regarding the company’s New Drug Application (NDA) for Lyrica (pregabalin) capsules CV as a monotherapy treatment for generalized anxiety disorder (GAD). The FDA determined that the data contained in the NDA were insufficient to support approval.
“We are disappointed with the FDA’s decision and will work with the agency to determine next steps,” said Steve Romano, vice president, Medical Affairs Head, Primary Care Business Unit. “Given the chronic nature of GAD and the number of patients who continue to experience anxiety symptoms despite treatment, there is a clear unmet need for new and different treatment options.”

Dec 29 · 2:41:00 PM · Source: Pharmabiz
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Enter your comment below and click Submit:

Copyright © 2010 MarketBeast.com.
All rights reserved.